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ABSTRACT
The differential display technique was used to identify mRNAs differ
entially expressed in human melanoma cell lines with different meta.statlc
capacity. We report the isolation of nine different clones, of which four
were uniquely expressed in the highly metastatic human melanoma cell
line MV3, whereas the other five clones were uniquely expressed In the
poorly metastatic human melanoma cell line 530. The differences in
expression identified by differential mRNA display were confirmed by
Northern blot analyses. DNA sequencing followed by computer search
analyses indicated that of the nine differenfially expressed clones, five
represented novel gene products. The other four were histocompatibility
antigen HLA-DR, laminin B2, melanoma inhibitory activity (MIA), and
tissue inhibitor of metalloproteinases 3. MIA was also identified In RNA
from human melanoma metastasis lesions in a comparison by differential
display with pooled human nevi. Northern blot analysis confirmed MIA
mRNA expression in nonmetastasizing melanoma cell lines and in mela
noma metastasis lesions, while expression was absent in highly metasta
sizing cell lines and pretumor stages. In the 11 metastasis lesions exam
mcd, MIA mRNA expression was apparently inversely correlated with
pigmentation.
INTRODUCTION
The incidence of human cutaneous melanoma increases more rap
idly than any other cancer in the last decade (1). All lesions are
thought to develop from melanocytes and represent subsequent stages
of progression accompanied by increasing atypia. An early primary
melanoma, characterized by horizontal growth (radial growth phase),
can develop into an advanced melanoma that is also capable of growth
in the vertical direction (vertical growth phase) and, eventually, of
metastasis. Extensive research efforts are invested to identify reliable
markers that should facilitate diagnosis of the neoplastic progression
stage and the design of efficient therapeutic strategies. The character
ization of relevant progression markers inherently provides better
insight in the tumor biology of melanoma.
In the last few years, we reported the isolation of several potential
progression markers, e.g., calcyclin (2), thymosin f310 (3), nma (4),
and timb (5) by applying differential and subtraction hybridization
techniques. As it is the case for other markers as well, the expression
profile of these genes is not unequivocal, but shows overlap between
different stages of tumor progression.
We applied the differential mRNA display method to obtain
additional informative progression markers. The differential
mRNA display technique is based on RT2-PCR and allows rapid
isolation of differentially expressed transcripts from two or more
cell types. The advantage of this technique lies in its ease of
operation and the minimal quantities of total RNA required for
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analysis. Furthermore, it gives access to transcripts of low abun
dance that are hardly or not detectable using subtractive hybrid
ization techniques (6, 7). By using human melanoma cell lines with
different metastatic capacities, the application of this method led to
the isolation of nine clones, which were uniquely or differentially
expressed either in the highly metastatic human melanoma cell
lines MV3 (8) and BLM (9), or in the poorly metastatic human
melanoma cell lines 530 and lF6 (9). From these clones, five
represented novel genes, whereas four clones were recorded genes.
One of the recorded genes, known as MIA was also identified by
using the differential mRNA display method to compare pooled
human metastases versus dysplastic nevi.
MIA was identified as a melanoma growth inhibitory activity in
the culture supernatant of a cell line derived from a human mela
noma metastasis in the central nervous system (10, 11). MIA is
secreted by a number of malignant melanoma cell lines and acts as
a potent growth inhibitor for malignant melanoma and other cell
lines (12).
Our results on expression in melanoma lesions characterize MIA as
an ontogenic melanoma marker apparently correlated with the loss of
pigmentation.
MATERIALS AND METHODS
Melanoma CeO Lines. Human melanoma cell lines MV3, BLM, 530,
and lF6 (8, 9) were grown as monolayers on DMEM (GIBCO Laboratories,
Grand Island, New York) supplemented with 10% FCS (GIBCO Labora
tories), glutamine (2 mM), penicillin G (100 units/ml), streptomycin (100
p@g/ml),and pyruvate (1 mM). Within this panel of cell lines, lF6 and 530
represent poorly metastasizing cell lines, with a metastasis frequency
of < 10% three months after s.c. inoculation into nude mice. The cell lines
BLMand MV3 represent the highly metastaticphenotype,with over 50%
metastasis frequency.
Human Tissues. Afterexcision, largepartsof melanomametastaseswere
immediately frozen in liquid nitrogen and stored at â€”80Â°C.Dissected mela
noma metastases were processed individually and were taken from patients
other than those from whom the nevi were removed. For RNA isolations from
dysplastic nevi, a representative slice was taken. Most of the skin surrounding
these lesions was cut off before freezing the material in liquid nitrogen. The
remainder was processed for conventional histopathology. Nevi were obtained
from patients without any history of melanoma, whereas normal skin was
obtained from patients who had also developed melanoma. When using nevi or
normal skin tissue, 6â€”22biopsies of 6â€”17patients were pooled to obtain
enough material.
RNA Isolation and Northern Blot Analysis. Total RNA was isolated
using the lithium-urea procedure as described by Auffray and Rougeon (13).
Ten @xgof total RNA were glyoxylated (14), size fractionated on 1% agarose
gels, and blotted to Hybond N-plus (Amersham, Aylesbury, United Kingdom).
To confirm that equal amounts were loaded in each lane, the blots were
hybridized afterwards with an 185 rRNA probe.
mRNA Differential Display. For differential display of mRNA, we used
the RNAmap protocol from GenHunter (Brookline, MA). Two hundred ng of
total RNA (after DNase treatment with the Message-Clean kit; GenHunter)
from the human melanoma cell lines MV3 and 530 were reverse transcribed in
a total reaction volume of 20 @xlcontaining 1X reverse transcriptase buffer
[125 msi Tris-HCI (pH 8.3), 188 mM KCI, 7.5 mM MgCl2, and 25 mM DTF],
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100 units of the Moloney murine leukemia virus reverse transcriptase (Life
Technologies, Gaithersburg, MD), 20 ,xM dNTPs and 20 pmol T@2MG, T12MC,
T@,MA,or T,,MT (where M may be dG, dC, or dA), respectively, as a primer.
Reactions were carried out in a Gene E thermocycler (Techne Limited,
Cambridge, United Kingdom): 65Â°Cfor 5 mm, 37Â°Cfor 1h, and then 95Â°Cfor
5 mm. Reverse transcriptase was added after 10 mm at 37Â°C.
One tenth of the cDNA was then amplified by PCR in a total volume of
20 @xlcontaining 1 X PCR buffer [10 mM Tris-HCI (pH 9.0) and 1.5 msi
MgCl2], 2 @xMdNTPs, 0.5 pA35S-dATP (Amersham), I unit Taq polym
erase (I unit/mI) using 20 pmol ofthe corresponding T12MN and 4 pmol of
an arbitrary 10 mer (AP 6â€”15).The samples were overlaid with 25 p1
mineral oil and subjected to 40 cycles of PCR in a Gene E thermocycler
using the following parameters: 94Â°C for 30 s, 42Â°C for 2 mm, and 72Â°C
for 30 5; the last cycle was followed by a 5-mm extension at 72Â°C.Two p.1
of loading dye were added to 3.5 p.1of the amplification products, heated
at 80Â°C for 2 mm, and loaded on a 6% DNA sequencing gel. Gels were
dried without fixation onto filter paper and subjected to autoradiography
using Kodak XAR-5 films.
We also applied the mRNA differential display to isolate differentially
expressed mRNAs in human dysplastic nevi and melanoma metastasis
lesions. Melanoma metastasis RNA consisted of a pool of metastases from
8 patients, whereas dysplastic nevi RNA was a pool of 17 lesions from 16
patients. Differential mRNA display was performed using RNA map kit B
(AP 6â€”10)as described above, except that [32P]dATP was used instead of
35S-dATP.
Recovery and Amplification. The cDNA bands representing differen
tially expressed mRNAs were excised from the gel, rehydrated in 100 p.1
distilled H,O for 15 mm, and boiled for 10 mm. Solid debris was removed
by centrifugation, and the cDNA in the supernatant was precipitated by the
addition of 10 p.1 3 M sodium acetate (pH 5.3), 5 p.1 glycogen (10 mg/ml;
Sigma Chemical, St. Louis, MO), and 450 p.1 100% ethanol. The pellet was
redissolved in 10 p.1 H,O. For each band, 4 p.1 extracted cDNA were
reamplified for 30 cycles in a total volume of 40 p.1 with the same primer
set and PCR conditions used in the initial RT-PCR, except that no radio
active dNTP was included. After PCR 30 p.1 of the samples were run on a
I.5% agarose gel and stained with ethidium bromide. PCR bands of the
expected size were cut from the gel, purified (15), and used as probes for
Northern blot analyses.
Cloning and Dot-Blot Selection. Unique or differential expression of the
reamplified PCR products in the human melanoma cell lines was checked by
Northern blot analyses, and the positive fragments were cloned into the pCRII
vector by the TA cloning system (Invitrogen, San Diego, CA) according to the
manufacturer's instructions. Selection of positive clones by the dot-blot pro
cedure was carried out as described by Callard et a!. (16) using the recovered
PCR fragments as probes.
DNA Sequencing and Computer Analyses. Cloned reamplified PCR
fragments were sequenced according to the dideoxy method as described by
Sanger et a!. (17) using a Sequenase sequencing kit (United States Biochem
ical, Cleveland, OH). Large fragments were sequenced by constructing a set of
deletion clones with exonuclease III (Erase-a-base kit; Promega, Madison,
WI). Identification of known sequences was performed using the Genbank and
EMBL data bases (18, 19).
Construction of cDNA Libraries. A cDNA library was constructed from
5 ,.tg oligodeoxythymidine-selected RNA using a AZap cDNA synthesis kit
(Stratagene, La Jolla, CA) according to the procedure recommended by the
manufacturer. Oligodeoxythymidine-selected RNA from the poorly metastatic
human melanoma cell line 530 was used for the construction of the 530 AZAP
cDNA library.
DNA Probes and Hybridization. DNA probeswere radiolabeledby the
random prime labeling method as described by Feinberg and Vogelstein (20).
Hybridization of cDNA libraries was performed according to standard proto
cols (15).
DNA Isolation and Southern Blot Analysis. Chromosomal DNA was
isolated according to the method of Blin and Stafford (21). DNA was
digested with EcoRI, and 10 p.g were size fractionated on 0.6% agarose
gels, transferred to Hybond N-plus, and hybridized as described previously
for Northern blot analysis. To check for equal loading of DNA, the blot was
hybridized afterward to a chromosome 18-specific centromeric probe. No
abnormalities involving chromosome 18 are known in relation to mela
noma.
RESULTS
Differentially Expressed mRNAs in Human Melanoma Cell
Lines. Human melanoma cell lines MV3 and 530 were used to isolate
potential melanoma progression markers. MV3 is a highly metastatic
human melanoma cell line, while 530 has a very low potential to
metastasize. To analyze the expression pattern of both cell lines by
RT-PCR, 40 different combinations of primer sets were used corn
posed of four degenerate anchored oligo(dT) primers (T12MG,
T,2MA, T12MC, or T12MT) and 10 short arbitrary 10 mers (AP
6â€”15). A total of 19 fragments was found to be uniquely expressed by
either of two human melanoma cell lines MV3 or 530. These cDNAs
fragments were reamplified by PCR and used as probes for hybrid
ization of Northern blots containing total RNA of the human mela
noma cell lines MV3 and 530. Of 19 MV3/530 differential display
products, 9 fragments were confirmed to be differentially or uniquely
expressed. A similar comparison of RNA from dysplastic nevi and
melanoma metastasis lesions yielded 12 differential display products,
of which only one was confirmed to be uniquely expressed by North
em blot analysis of the human melanoma cell lines MV3 and 530. The
differential display of the 9 + 1 PCR-amplified cDNAs (clones 1â€”10),
which detect uniquely or differentially expressed mRNAs on a North
em blot, is shown in Fig. 1. Some fragments appeared to be doublets
or even sets of three or four bands with nearly the same intensity.
These bands represent the two strands of one fragment and probably
result from an additional A known to be added by Taq polymerase.
The 9 + 1 PCR fragments that detected differentially expressed
mRNAs between the human melanoma cell lines MV3 and 530 were
cloned into the TA cloning vector, and recombinants were selected by
the dot-blot procedure. The cloned PCR fragments were used as
probes to hybridize a Northern blot containing total RNA of two
highly metastatic (MV3 and BLM) and two poorly metastatic (1F6
and 530) human melanoma cell lines. As shown in Fig. 2, clone 1
detected a 1.7-kb transcript expressed only in 530 cells (Fig. 2A).
Clone 2 detected a 1.8-kb transcript highly expressed in 530, weakly
in 1F6, and not detectable in MV3 and BLM cells (Fig. 2B). A 4.6-kb
transcript was detected by clone 3, showing high expression in BLM
and modest expression in MV3 while expression was absent in 530
and lF6 cells (Fig. 2C). Clone 4 detected a 0.55-kb transcript present
only in 530 and lF6 cells (Fig. 2D). Clone 5 displayed a weak
expression in MV3 and even weaker expression in BLM cells of a
0.45-kb transcript (Fig. 2E). Clone 6 detected a 2.0-kb transcript only
present in 530 and lF6 cells (Fig. 2F). A 5.0-kb transcript was
detected by clone 7, with a high expression in BLM and weakly
detectable in MV3 and 1F6, whereas expression was absent in 530
cells (Fig. 2G). Clone 8 detected a 4.4-kb transcript highly expressed
in 1F6, moderately in 530, and very weakly in MV3 and BLM cells
(Fig. 2H). A 4.7-kb transcript was detected only in the MV3 and BLM
cells by clone 9 (Fig. 2!). Clone 10 detected a 0.55-kb transcript only
in the 530 and 1F6 cells (Fig. 2./).
DNA Sequencing and Computer Analysis. All 10 differentially
expressed cDNA fragments were analyzed by DNA sequencing (data
are shown in Fig. 3). DNA sequencing revealed that clones 4 and 10
are identical. A computer search against Genbank and EMBL DNA
data bases revealed that three clones (clones 2, 5, and 6) had no
significant homology to any DNA sequences. Clone 1 showed 99%
homology to human mRNA for the histocompatibility antigen
HLA-DR (a chain; Ref. 22). Clone 3 showed 96.5% homology (11
mismatches; 3 at the upstream AP-9 primer) to a 518-bp human
cDNA clone (EMBL accession no. T57750). Both clones 4 and 10
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Fig. I. Differential mRNA display using total RNA isolated from human melanoma cell lines 530 (Lanes 1), MV3 (Lanes 2), pooled human melanoma meta.stases (Lanes 3), and
dysplastic nevi (Lanes 4). Total RNA was reverse transcribed, followed by PCR amplification in the presence of l35Sl-dATP (A-I) or l32P)dAl'P (J). The PCR fragments were
fractionated on 6% DNA sequencing gel and autoradiographed as detailed in â€œMaterialsand Methods.â€•Primers used are: A, clone I (cl. 1) AP-91F,2MC; B, clone 2 (cl. 2) AP-7/1',2MC;
C, clone 3 (ci. 3) AP-9/T,,MT; D, clone 4 (cI. 4) AP-6T1',,MC; E, clone 5 (cl. 5) AP.81r,2MT; F, clone 6 (cl. 6) AP-IOR',2MG; G, clone 7 (ci. 7) AP-12/T,2MT; H, clone 8
(cl. 8) AP-12!F,,MT; I, clone 9 (ci. 9) AP-l5IT,2MT; and J, clone 10 (cl. 10) AP-6/T,,MC. Arrows, cDNA fragments.
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Fig. 2. Northem blot analysis of a panel of four human melanoma cell lines with differential display products as probes. Ten @zgof total RNA were loaded in each lane. Lanes 1,
530; Lanes 2, lF6; Lanes 3, BLM; Lanes 4, MV3. Blots A-i were hybridized to cloned PCR fragments 1â€”10,respectively. The molecular weight marker was ADNA digested with
restriction endonuclease Hindlil. As a control for the amount of RNA loaded in each lane, an l8S rRNA hybridization is shown.
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clonâ€¢ 1
1 cgtczacaata tgacctcagt gaaagcagtc
51 ttttccagcc ctatagccac ctcaagtgtg gttatgcctc ctcgattgct
101 ccgtactcta acatctagct ggcttccctg tctattgcct tttcctgtat
151 ctattttcct ctatttccta tcattttatt atcaccatgc aatgcctctg
201 gaataaaaca tacaggagtc tgtctctgct atggaatgcc ccatgactct
251 cttgtgtact tattgtttaa ggtttcctca aactgtgatt ttctgaacac
301 aataaactat ttgatgatct tgggtggaaa aaaaaaaaa
don. 2
1 ccaaagaatg aaaagagagc tctaaccaga tggaacactg gaacattcca
51 gtggaccctg gaccattcca ggaaaactgg gacataggat cgtcccgcta
101 tgatggaagt gttcagacag tttataatag taagcccctg tgaccctctc
151 acttaccccg agacctcact ttattacaag atctttccaa atacccaaat
201 gtccctgcaa gcccgttaaa taattcccta tgctaccctt
251 aatgaccaca tagtgtgaga acttccaaca agcctcaaag tcccttgaga
301 ctccccaata cctaataagg catgcgaaat gttctcatga actaccccac
351 aacacgccta aaactcaaaa cacccaaaaa tacctcctcc aatgtcctga
401 aacatgaacc caaaaagaga cccacaataa actcgtgact tgtccQg@5.@
451 aaaaaaaaa
clone 3
1 ggtoocaata gagagagtta tgctacaatt atttcttggt ttccacttgc
51 aatggttaat taagtccaaa aacagctgtc agaacctcga gagcagaaca
101 tgagaaactc agagctctgg accgaaagca gaaagtttgc cgggaaaaaa
151 aaagacaaca ttattaccat cgattcagtg cctggataaa gaggaaagct
201 tacttgttta atggcagcca catgcacgaa gatgctaaga agaaaaagaa
251 ttccaaatcc tcaacttttg aggtttcggc tctccaattt aactctttgg
301 caacaggaaa caggttttgc aagttcaagg ttcactccct atatgtgatt
351 ataggaattg ttgtggaaat ggattaacat acccgtctat gcctaaaaga
401 taataaaact gaaatatgtc ttcacaaaaa aaaaaaa
clone 4
1 gcaatcgatg tgaagacaga caaatgggat ttctactgcc agtgagctca
51 gcctaccgct ggccctgccg tttcccctcc ttgggtttat gcaaatacaa
101 tcagcccagt ocaaaaaaaa aaaa
clone 6
1 tagcaagtgc
51 agatcggcaa aggaaaccaa
101 gggtagctga ttatgaggaa
151 tagtaatggt ctacaataag
201 ctcccaaaaa aapaaaa
clone7
1 tgctgacctg gagaatgaag ccaa@aagca ggtaggctgc cattatggac
51 tataaccgag atatcgagga gatcatgaag gacattcgca atctggagga
101 catcaggaag accttaccat ctggctgctt caacaccccg tccattgaaa
151 agccctagtg tctttagggc tggaaggcag catccctctg acaggggggc
201 agttgtgagg ccacagagtg ccttgacaca aagattacat ttttcagacc
251 cccactcctc tgctgctgtc catccactgt ccttttgaac caggaaaagt
301 cacagagttt aaagagaagc aatttaaaca tcctgaatcg ggaacaaagg
351 gttttatcta ataaaagtgt ctcttccata aaaaaaaaaa a
clone8
1 tgctgacctg aaacccagaa gtgatggaga gaaaccaaca agagatctcg
51 aaccctgtct agaaggaatg tatttgttgc taaatttcgt agcactgttt
101 acagttttcc tccattttat ttatgaattt tatattccgt gaatgtatat
151 tgtcttgtaa tgttgcataa tgttcacttt ttatagtgtg tcctttattc
201 taaacagtaa agtggtttta tttctatcac aaaaaaaaaa aa
clone 9
1 agaocctgtt ggggaagtgg gagatagagg agatattggt taaaggatag
51 aaaattttag ttagacaaga ggaataagtt caagaatatt gtctaacatg
101 gtgactatac ttacaacaac aactgcatta atgatatatt tgtacttgaa
151 atttgcttag agtagattta gtgtttaccc acaaaaaaaa papa
clone10
1 ocaatcgatg tgaagacaga caaatgggat ttctactgcc agtgagctca
51 gcctaccgct ggccctgccg tttcccctcc ttgggtttat gcaaatacaa
101 tcagcccagt gcaaaaaaaa aaaa
Fig. 3. Partial cDNA nucleotide sequence of 10 mRNAs differentially expressed in
human melanoma cell lines with different metastatic potential. Flanking sequences rep- 296 323
S â€¢ S S S . TTC TCC AAG CTG AAG GGC CGT GOG CGG CTC TTC TGG GGA GGC SOC GTT CAG GGA
resenting pnmer sets used for PCR amplification are underlined. The GenBank accession Phe Ser Lys Leu Lys Gly Arg Gly Arg Leu Phe Trp Gly Gly Ser Val Gin Gly
numbers for the novel clones are: clone 2, U3l2l4; clone 3, U3O999; clone 5, U3l000;
clone 6, U30998; and clone 9, U3IOOI. 350 377
GAT TAC TAT GGR OAT CTG GCT GCT CGC CTG GGC TAT TTC CCC AGT AGC ATT GTC
Asp Tyr Tyr Gly Asp Leu Ala Ala Arg Leu Gly Tyr Phe Pro Ser Ser lie Val
404 431
CGA GAG GAC CAG ACC CTG AAA CcT GGC AAA GTC OAT GTG AAG ACA GAC AAA T@
Arg Glu Asp Gin Thr Leu Lys Pro Gly Lys Val Asp Val Lys Thr Asp Lys Trp
458 485
OAT TrC TAC TGC CAG TGA GCT CAG CCT ACC GCT GGC CCT GCC GT@ TCC CCT CCT
Asp Phe Tyr Cys Gin
512
TOG OTT TAT OCA AAT ACA ATC AGC CCA GTG C (A n
Fig. 4. cDNA sequence ofpJG46O (human MIA). 5' and 3' extensions to the published
sequence by Bleach et al. (12) are underlined.
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rized data on the isolation of these 10 clones, their expression pattern,
and computer search results are listed in Table 1.
Characterization of MIA. Clones 4 and 10 (MIA) were identified
by the differential display technique when using melanoma cell lines
with different metastatic capacities (clone 4) and also by using pooled
melanoma metastases versus pooled dysplastic nevi (clone 10). Clone
4 was analyzed in more detail. A cDNA library was constructed from
the poorly metastatic human melanoma cell line 530. The library had
a complexity of 4 X 106 recombinant clones, with an average insert
length of 1.7 (range, 0.9â€”3.4)kb. The cDNA insert of clone 4 was
used as a probe to screen a 530 AZap cDNA library, resulting in the
isolation of a 0.55-kb cDNA clone, designated pJG46O. DNA se
quencing (Fig. 4) and computer data base search revealed, as cx
pected, that this cDNA was identical to mRNA for MIA (12), while
our MIA cDNA clone is extended at the 5' end with 14 nucleotides
(positions 1â€”14)and at the 3' end with 43 nucleotides (positions
474â€”516, poly(A) tail excluded).
To exclude the possibility that gene amplifications or rearrange
ments could be responsible for the differences in MIA mRNA
expression between poorly and highly metastatic human melanoma
cell lines, we hybridized a Southern blot containing EcoRI-di
gested genomic DNA from a panel of human melanoma cell lines
with the 0.55-kb MIA cDNA insert of pJG46O. A 17-kb EcoRI
fragment was detected by the 0.55-kb MIA cDNA insert (Fig. 5).
The hybridization pattern of MIA is comparable for the different
human melanoma cell lines (with only a slight elevation of MIA
signal in BLM cells).
The expression of MIA in human melanocytic lesions was
examined by a Northern blot analysis of several human melano
cytic metastases and nevi. From 11 melanoma metastases, 8 (Fig.
6, Lanes G, 1, J, K, L, N, 0, and P) were used as a pool for mRNA
differential display. Total RNA was hybridized with the 0.55-kb
MIA cDNA insert of pJG46O as a probe (Fig. 6). MIA mRNA is
not detectable in melanocytes (Fig. 6, Lane A), normal skin (Fig.
6, Lane B), dysplastic nevi (Fig. 6, Lane C), and 2 (Fig. 6, Lanes
26 53
Go AAA rrc GAG ACC CCA GCA CCC CCT TGC TCA CTC TCT TGC TCA CAG TCC ACG
80 107
ATO GCC CCC TCC CTG GTG TGC CTT GOT GTC ATC ATC TTG CTG TCT GCC TTC TCC
Met Ala Arg Ser L.eu Val Cys Leu Gly Val lie lie Leu Leu Ser Ala Phe Ser
134 161
GGA CCT GOT GTC AGO GOT GOT CCT ATG CCC AAG CTG GCT GAC COG AAG CTG TGT
Gly Pro Gly Val Arg Gly Gly Pro Met Pro Lys Leu Ala Asp Arg Lys Leu Cys
188 215
GCG GAC CAG GAG TGC AGC CAC CCT ATC TCC ATG GCT GTG GCC CTT CAG GAC TAC
Ala Asp Gin Glu Cys 5cr His Pro lie 5cr Met Ala Val Ala Leu Gin Asp Tyr
242 269
ATG GCC CCC GAC TGC CGA TTC CTG ACC ATT CAC CGG GGC CAA GTG GTG TAT GTC
Met Ala Pro Asp Cys Arg Phe Leu Thr Ile His Arg Giy Gin Val Val Tyr Vai
clone 5
1 ggattgtgcg
51 tcccaacctt
101 attttgccct
151 tcattttgaa
201 aatataaact
251 ataaagactt
atgttatgtt
atgttaaaag
ttattgagga
ataatcagca
gttatgcct t
acaaaaagga
catgttaatc
agagaagtaa
accagatttg
agttgaggta
cagtgcatta
gtattttccc
gatgggaaag
gttctgtaaa
aataagaaag
ctgcacacac
ctatttgtaa aatgaagtgt
ataacagact gtattcagtt
tcttcttttt gtttgtaatc
cttcttcaaa tgctttgtac
ctatgggagg agcaagaaaa
acaaaaaaaa aaaa
ctaaaatggg
atgagttctc
agctttgctt
acatccctca
tatgtacata
cctccctcca
ttctccttag
tcaCacctCt
showed 97.5% homology (three mismatches at the upstream AP-6
primer) to human mRNA for MIA (12). Clone 7 showed 98% homol
ogy (four mismatches; two at the upstream AP-l2 primer) to human
mRNA fragment for laminin B2 (23). Clone 8 showed 99.6% homol
ogy (one mismatch at the upstream AP-12 primer) to human TIMP-3
(24, 25). Clone 9 showed 69% homology to the human cytotoxic
senne protease B (CSP-B) gene flanking sequence (data base acces
sion no. M62716). All clones were, as expected, flanked by the
sequences of the primer set used for PCR amplification. The summa
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siOn of clone 10 (MIA) human metastases. We were unable to
detect MIA mRNA expression on a Northern blot containing total
RNA from human kidney, lung, liver, placenta, spleen, prostate,
and colon (results not shown).
DISCUSSION
This article describes the use of the differential mRNA display
technique to identify potential progression markers for human mela
noma. The analysis comparing the poorly metastatic cell line 530
versus the highly metastatic cell line MV3 yielded five cDNA frag
ments with unique expression in the poorly metastatic cell line 530
and four cDNA fragments uniquely expressed in the highly metastatic
cell line MV3 (Fig. 1). Northern blots containing total RNA from a
panel of human melanoma cell lines characterized for metastatic
behavior confirmed the correlation between expression of these
cDNA fragments and metastatic potential. Sequence analysis of the
cDNA fragments revealed five clones to represent novel genes,
whereas four clones represented reported genes.
Clone 4, detecting a 0.55-kb transcript in the poorly metastatic
human melanoma cell lines 530 and 1F6 (Fig. 2D) is identical to
the MIA gene (Table 1), a potent growth inhibitor for melanoma
and other cells (10â€”12). The MIA cDNA fragment did not only
emerge from the differential display analysis of mRNA present in
the poorly metastasizing cell line 530 versus the highly metastatic
cell line MV3, but also from a second analysis comparing pooled
human nevi and pooled metastases. Surprisingly, in this analysis
MIA mRNA expression was exclusively detected in pooled human
metastases. Additional Northern blot analysis confirmed this par
adoxical expression pattern: MIA is expressed in nonmetastasizing
melanoma cell lines in culture (representative of the radial growth
phase) and in melanoma metastasis lesions, while it is virtually
absent in frequently metastasizing cell lines (representative of the
vertical growth phase) and pretumor stages. The differences in
MIA mRNA expression between poorly and highly metastasizing
cell lines cannot be ascribed to major chromosomal rearrange
ments. MIA is apparently not expressed in normal somatic cells of
adult organisms (see â€œResultsâ€•and Ref. 12). While Blesch et al.
(12) reported MIA mRNA to be expressed in every melanoma cell
line tested, in our panel of human melanoma cell lines MIA mRNA
expression is restricted to poorly metastasizing cell lines. This
would suggest it to be a potential marker for early stages of
melanoma progression. Its presence in a considerable number of
human melanoma metastasis lesions would be in contrast with this
suggestion. Other potential early progression markers, notably
nm23 (26, 27), nma (4), and nmb (5) display a similar expression
distribution. One could speculate that these genes and MIA may be
involved in attenuating metastatic properties of melanoma cells,
possibly as a consequence of tumor-host interactions. Tumor pro
gression may require that genes are (temporarily) switched off in
the course of metastasis, but turned on again later in a secondary,
distantly growing tumor (4). In the limited number of lesions
analyzed, it seems that MIA mRNA expression is inversely corre
lated with pigmentation of melanoma metastases, and because loss
of pigmentation can be considered as a consequence of dediffer
entiation, MIA may be regarded as a dedifferentiation marker.
Immunohistochemical analysis of melanoma lesions may clarify
this apparent paradox.
mRNA expression of clone 1 was only detected in the poorly
metastatic human melanoma cell line 530 (Fig. 2.4) and appeared to
be identical to human histocompatibility antigen HLA-DR (Table 1).
The cloning of this cDNA fragment is likely explained by the fact that
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Fig. 5. Southern blot analysis of several human melanoma cell lines. Ten @sgEcoRl
digested chromosomal DNA were loaded in each lane. Lane A, 530; Lane B, lF6; Lane
C, BLM; Lane D, MV3. The blot was hybridized to a radiolabeled 0.55-kb MIA cDNA
insert of pJG46O. The molecular weight marker was ADNA digested with restriction
endonuclease Hindlll. As a control to the amount of DNA loaded in each lane, a
chromosome 18-specific centromeric hybridization is shown (three bands of approxi
mately 20, 1.3, and 0.6 kb are visible). Abnormalities involving chromosome 18 were not
described in relation to melanoma.
@,.
J and L) of 1 1 melanoma metastases. MIA mRNA expression is
either absent or weak in melanoma metastases with strong pigmen
tation (Fig. 6, Lanes I, J, L, and M), whereas expression was
moderate in melanoma metastases with weak pigmentation (Fig. 6,
Lanes F and N) and high in melanoma metastases with no pig
mentation (Fig. 6, Lanes G, H, K, 0, and P). This could suggest a
correlation between pigmentation and MIA mRNA expression in
melanoma metastases. The results of the Northern blot analysis of
the human melanocytic lesions confirm the differential display of
melanoma metastases and dysplastic nevi, showing unique expres
Table IIsolation of differentialexpressed mRNAs inhuman melanomacellsClonePCR
primers (5' â€”Â°3')Fragmentsize (bp)Northem
blot expressionmRNA
size (kb)Homologous
by
computersearch5301F6MV3BLMcl.
IAP9:CGTOGCAATA344+++.,-- --1 .5Human mRNA for histocompatibility antigen HLA-DR(99%)T,2MCcl.2AP7:CCGAAGGAAT459.â€˜-+++.â€˜-+
--1.8NovelT12MGcl.3AP9:CGTGGCAATA437â€”â€”
++i-i--i-s4.6Human cDNA clone 79197 3' end(97.5%)T12MTcl.4AP6:GCAATCGATGI
24+++ --0.55Human mRNA for melanoma growth regulatory protein MIA(97.5%)T,,MCcl.5AP8:GGAUGTGCG294â€”â€”
+1â€”i-Iâ€”0.45NovelT12MTcl.6AP1O:TAGCAAGTGC217++-e-+++++
â€”â€”2.0NovelT12MGcl.7AP12:TGCTGACCTG389â€”+
+Ã·++5.0Human mRNA fragment for laminin B2(98%)T12MTcl.8API2:TGCTGACCTG242++++
--4.4Human mRNA for TIMP-3(99.6%)T12MTcl.9API5:AGGGCCTGTF194â€”â€”
i-s++4.7Human cytotoxic senne protease B (CSP-B) gene(69%)TJ,MTcl.lOAP6:GCAATCGATG124++
â€”â€”0.55Human mRNA for melanoma growth regulatory protein MIA(97.5%)T12MC
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Fig. 6. Northem blot analysis of human cutane
ous melanocytic lesions. Ten gig of total RNA were
loaded in each lane. Lane A, melanocytes; Lane B,
normal skin (13 biopsies from 12 patients); Lane C,
dysplastic nevi (6 lesions from 6 patients); Lane D,
xenograft derived from radial growth phase; Lane
E, xenograft derived from vertical growth phase;
Lanes F-P. melanoma metastases. Pigmentation
was strong in the metastases in Lanes I, J, L, and M;
weak in Lanes F and N; and absent in Lanes G, H,
K, 0, and P. The blot was hybridized to a radiola
beled 0.55-kb MIA cDNA insert from pJG46O. The
molecular weight marker was ADNA digested with
restriction endonuclease HindIII. As a control to
the amount of RNA loaded in each lane, an 185
rRNA hybridization is shown. Densitometric scan
ning showedthat the maximumvariationin l8S
rRNA loading (between Lanes L and D) was not
more than 3-fold, whereas this was 100-fold for
MIA mRNA (between Lanes M and K, Lanes A, B,
C, J, and L being negative). Pigmentation was
scored by eyeball estimation of the pigment mela
nm intensity in the RNA samples. Pigmentation
comparable to melanocyte samples was identified
as strong; less pigmentation is scored as weak.
9-4-
6.6-
4.3-
2.3-
2.0-
0.6-
18S
rRNA
cellular functions. Overproduction of TIMP- 1 and TIMP-2 sup
pressed metastatic ability in vivo and markedly reduced tumor
growth rate while completely suppressing local invasion (30, 31).
We found only a strong TIMP-3 mRNA expression in the poorly
metastatic human melanoma cell lines 530 and lF6 and no expres
sion in MV3 and BLM cells. These results suggests TIMP-3 to be
a potential progression marker for early stages of melanoma de
velopment.
Our data substantiate that differential display is a powerful and fast
technique to analyze gene expression and to identify both activated
and repressed gene fragments from the same reaction. The low
amounts of RNA required would even allow a direct comparative
analysis of human lesions with a probability to detect early changes
crucial for tumor progression. Further characterization of the novel
genes and the two recorded genes MIA and TIMP-3 in regard to their
biological functions should lead to a better understanding of the tumor
biology of human cutaneous melanoma.
the human melanoma cell lines MV3 and 530 originated from differ
ent patients.
Clone 8, detecting a 4.4-kb transcript in the poorly metastatic
human melanoma cell lines 530 and lF6, appeared to be homolo
gous to human TIMP-3 (Table 1). For TIMP-3 three transcripts of
2.2, 2.5, and 4.4 kb have been reported, probably as a result of
alternative splicing or the presence of extended 3' or 5' untrans
lated regions in the TIMP-3 mRNA (24, 25). Clone 8 detected only
the 4.4-kb transcript, and this indicates that the isolated 3' end of
the cDNA is absent in the two shorter mRNAs. TIMP-3, along with
TIMP-1 and TIMP-2, belongs to a family of related but distinct
genes functioning as naturally occurring inhibitors of matrix met
alloproteinases, a group of enzymes implicated in degradation of
the extracellular matrix (28). An imbalance between proteinases
and their activators or inhibitors has been implicated in tumor
invasion (29). Manipulation of the balance between matrix metal
loproteinases and their inhibitors can induce or suppress abnormal
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